- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
COA Releases Statement on Prescription Drug Pricing Reduction Act
On behalf of the Community Oncology Alliance (COA), Ted Okon, executive director of COA, has released a statement regarding the Prescription Drug Pricing Reduction Act.
On behalf of the Community Oncology Alliance (COA), Ted Okon, executive director of COA, has released a statement regarding the Prescription Drug Pricing Reduction Act. While COA supports certain provisions in the package, including encouraging a healthy and competitive biosimilars market, transparency around pharmacy benefit managers, and changes to grandfathered site-neutral payments for hospitals, there are some provisions COA is opposed to. For example: the proposal to include support from patient assistance programs in the calculation of Average Sales Price, which is the basis for Medicare Part B drug reimbursement.
According to Okon, the provision would lead to drug manufacturers to reduce or eliminate programs. Read the full press release.
Mental Health Awareness: Transforming Workplace Support and Engagement
May 20th 2025Explore how employers enhance workplace mental health by fostering a culture of support and engagement, focusing on holistic well-being strategies in this interview with Jim Kinville, MA, University of Pittsburgh Medical Center.
Listen
Community Oncology Reacts to Trump's Drug Pricing Executive Order
May 2nd 2025An executive order signed on Tuesday, March 15, necessitated a change in plans for this panel discussion from the 2025 Community Oncology Conference, with the assembled experts, moderated by Ted Okon, MBA, executive director of the Community Oncology Alliance, speaking to how the order would reverberate across the community oncology space.
Read More
